This signaling axis also offers a vulnerability targetable by small-molecule PAK inhibitors, such as ATP-competitive PF-3758309 14, 15, which enables inhibition on growth and angiogenesis of myxofibrosarcoma through suppressing expression and phosphorylation of PAK1 to downregulate CSF2 transactivation. Here, CSF2 is linked to myxofibrosarcoma.